Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
Study sponsor: Supernus Pharmaceuticals, Inc. · SUPN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2019-11-15Actual
Enrollment · participants297Actual
Source updated2024-03-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.